Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Stock Report

Market Cap: US$6.6b

Intra-Cellular Therapies Balance Sheet Health

Financial Health criteria checks 5/6

Intra-Cellular Therapies hat ein Gesamteigenkapital von $600.7M und eine Gesamtverschuldung von $0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen $717.7M bzw. $117.0M.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$497.94m
EquityUS$591.42m
Total liabilitiesUS$136.87m
Total assetsUS$728.30m

Recent financial health updates

Recent updates

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17
After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Dec 24
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular's Second FDA Win Makes It A Great Long-Term Investment

Dec 21

Intra-Cellular Therapies: A Leader In The Psychiatric Medicine Space

Nov 08

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Aug 06
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

We Think The Compensation For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Looks About Right

Jun 15
We Think The Compensation For Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) CEO Looks About Right

Intra-Cellular Therapies (ITCI) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow

Jun 04

FDA accepts Intra-Cellular Therapies' lumateperone applications for bipolar depression

May 03

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Mar 23
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Financial Position Analysis

Kurzfristige Verbindlichkeiten: ITCIDie kurzfristigen Aktiva des Unternehmens ($702.4M) übersteigen seine kurzfristigen Passiva ($103.1M).

Langfristige Verbindlichkeiten: ITCIDie kurzfristigen Vermögenswerte des Unternehmens ($702.4M) übersteigen seine langfristigen Verbindlichkeiten ($13.9M).


Debt to Equity History and Analysis

Verschuldungsgrad: ITCI ist schuldenfrei.

Schulden abbauen: ITCI hatte vor 5 Jahren keine Schulden.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stabile Start- und Landebahn für Bargeld: ITCI auf der Grundlage seines derzeitigen freier Cashflows über eine ausreichende Liquiditätsreserve für mehr als 3 Jahre verfügt.

Vorhersage Cash Runway: Unzureichende Daten, um festzustellen, ob ITCI über genügend Cash Runway verfügt, wenn sein freier Cashflow auf der Grundlage historischer Raten weiter wächst oder schrumpft.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.